The health technology assessment and access landscape in the EU is undergoing significant change—reflected in both the implementation of the Joint Clinical Assessment (JCA), which will be applied to all medicinal products by 2030, and proposed changes to the EU pharmaceutical legislation. The legislative changes are expected to impact many market aspects, including market exclusivity length, sequence of launch, supply chain, value assessment and pricing approaches, to name a few.
In this webinar, together with a panel of industry leaders, we will:
- Explore the potential scenarios that may arise as a result of these changes
- Discuss how best the pharmaceutical industry can prepare to mitigate potential risks and seize any opportunities that may present themselves
- Understand how these changes might alter the industry’s approach to the EU market going forward
Add insights to your inbox
We’ll send you content you’ll want to read – and put to use.
